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Abstract
Background: Ovarian epithelial cancer (OEC) usually presents in the later stages of the disease. Factors, especially
those associated with cell-cycle genes, affecting the genesis and tumour progression for ovarian cancer are largely
unknown. We hypothesized that over-expressed transcription factors (TFs), as well as those that are driving the
expression of the OEC over-expressed genes, could be the key for OEC genesis and potentially useful tissue and
serum markers for malignancy associated with OEC.
Methods: Using a combination of computational (selection of candidate TF markers and malignancy prediction)
and experimental approaches (tissue microarray and western blotting on patient samples) we identified and
evaluated E2F5 transcription factor involved in cell proliferation, as a promising candidate regulatory target in early
stage disease. Our hypothesis was supported by our tissue array experiments that showed E2F5 expression only in
OEC samples but not in normal and benign tissues, and by significantly positively biased expression in serum
samples done using western blotting studies.
Results: Analysis of clinical cases shows that of the E2F5 status is characteristic for a different population group
than one covered by CA125, a conventional OEC biomarker. E2F5 used in different combinations with CA125 for
distinguishing malignant cyst from benign cyst shows that the presence of CA125 or E2F5 increases sensitivity of
OEC detection to 97.9% (an increase from 87.5% if only CA125 is used) and, more importantly, the presence of
both CA125 and E2F5 increases specificity of OEC to 72.5% (an increase from 55% if only CA125 is used). This
significantly improved accuracy suggests possibility of an improved diagnostics of OEC. Furthermore, detection of
malignancy status in 86 cases (38 benign, 48 early and late OEC) shows that the use of E2F5 status in combination
with other clinical characteristics allows for an improved detection of malignant cases with sensitivity, specificity,
F-measure and accuracy of 97.92%, 97.37%, 97.92% and 97.67%, respectively.
Conclusions: Overall, our findings, in addition to opening a realistic possibility for improved OEC diagnosis, provide an
indirect evidence that a cell-cycle regulatory protein E2F5 might play a significant role in OEC pathogenesis.
Background
Ovarian epithelial cancer (OEC) remains the most lethal
gynecological malignancy in Western countries [1,2].
Poor prognosis is due to the late stage at first presenta-
tion, and advances in surgery and chemotherapy have
had small impact on survival. In contrast, patients who
present with early-stage disease have a five-year survival
of up to 95% after surgery alone, and may even be
spared the toxic side effects of postoperative adjuvant
chemotherapy [3]. Early detection of this lethal disease
remains the most promising approach to improve the
long-term survival and quality of life of patients with
OEC [4]. Serum CA125 is a good tumor marker for
monitoring patients with ovarian cancer after they have
been appropriately treated, but is a poor biomarker for
screening and detection of early OEC [5]. Screening
strategies are being explored for the early detection of
epithelial ovarian cancer, but these appear to still have
limitations in their detection and high false positive
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rates [6,7]. Although susceptibility genes, such as
BRCA1 and BRCA2, have been identified, a majority of
ovarian cancers occur sporadically without known risk
factors [8].
Over the past few years several groups have reported
potential of gene expression profiling based on microar-
rays to study the expression patterns of different genes
during onset of ovarian cancer [9,10]. Some of these
markers identified using this technique are: (1) prostasin
a serum marker for ovarian cancer [11]; (2) Mesothelin
(MSLN) [12,13], (3) WFDC2 (HE4) a glycoprotein [14]
(4) osteopontin [15]; (5) Bikunin [16]; (6) mammaglo-
bin-2 (MGB2) [17]; (7) discoidin domain receptor 1
(DDR1) [18]; (8) claudin 3 (CLDN3) [18]; (9) epithelial
cell adhesion molecule (Ep-CAM) [18]; and (10) E-cad-
herin [18]. These markers were studied individually and
not examined as part of the whole process of oncogen-
esis that would provide compelling evidence of their
role in the disease process, and their utility as potential
OEC biomarkers.
There is vast amount of gene expression profiling data
available in the public domain, as well as in various pri-
vate databases for ovarian cancer [9]. More recently,
focused efforts were made to exploit these vast valuable
resources to identify potential markers for various can-
cers [19,20]. These strategies save precious time and
avoid unnecessary duplication of experiments and,
moreover, can help focus on the most promising
experiments.
Cell-cycle genes and associated regulatory factors
which play a key role in cancers are a key target for
most of biomarker discovery efforts [21-23]. Cell-cycle
machinery controls cell proliferation, and cancer is a
manifestation of disrupted cell proliferation. Different
phases in cell-cycle (G1, G1-S, S, and G2-M), show
activities of several oncogenes and tumor suppressor
genes that display a range of abnormalities with poten-
tial usefulness as markers of genesis and as prognostic
markers for ovarian cancer [22]. Transcription factors
(TFs) control the expression of various genes during
these different phases of cell-cycle.
Previous reports have focused mostly on secretory
proteins as markers of OEC. However, most of such
proteins were ineffective in diagnosing the disease early.
More recently, the use of TFs as markers for the disease
itself have been reported and they have been detected in
the blood [24-26]. In our study, the strategy was to
investigate the regulatory mechanism of genes impli-
cated by expression data as specific to OC and in this
way to identify the key TFs associated with this malig-
nancy which could aid in discriminating malignant con-
dition from benign and healthy conditions. We
hypothesized that over-expressed TFs, as well as those
that are driving the expression of the OEC over-
expressed genes, could be the key for OEC genesis and
potentially useful tissue and serum markers for malig-
nancy associated with OEC. The identified TFs in this
study participate in a common control mechanism of
several key over-expressed genes, such as keratins which
are themselves involved in the cell structural integrity.
The molecular processes during OEC might ultimately
result in the release of oncoproteins into blood stream,
particularly if implicated TFs are involved in the regula-
tion of genes responsible for structural properties of
extracellular matrix as are keratin encoding genes, or if
they are themselves controlled in the similar fashion as
such genes. The results of our bioinformatics analysis to
determine relevant TFs guided by the gene expression
results, is followed up by extensive experiments based
on clinically relevant cases and revealed among the
identified TFs, E2F5 that demonstrates a strong poten-
tial to improve diagnostics of OEC.
Methods
Patient serum samples
A total of 88 women, aged between 20 and 72 years, 40
benign, and 48 malignant cases (16 early, and 32 late
cases) (Table 1) were recruited for open surgical or
laparoscopic treatment at the Department of Obstetrics
and Gynecology, National University Hospital, Singa-
pore), from 1998 to 2006. The histologic type of ovarian
cancer were classified as defined by International Fed-
eration of Gynecology and Obstetrics [27] staging [27]
[FIGO Cancer Committee (1986).]. A total of 56 normal
volunteers were recruited as controls that were diag-
nosed to have no cyst or any other type of malignancy.
Table 1 Clinical characteristics and age distribution of study samples (serum samples) used for E2F5 and CA125
expression studies.










Normal 56 45.00 ± 15.00
Benign 40 42.80 ± 16.65 5 11 14 0 10
Stage I/II 16 50.94 ± 12.16 2 4 6 3 1
Stage III/IV 32 52.32 ± 10.11 19 1 9 3 0
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Venous blood from case and control groups (normal
volunteers) were collected in 8-ml Vacuette serum tubes
containing clot activating factor (Greiner Bio-One,
Kremsmuenster, Austria). Tissue samples from cysts of
ovarian carcinomas and benign ovarian cysts were col-
lected during surgery without intraoperative spillage,
and the histology confirmed by a pathologist. All sam-
ples were transported on ice to the laboratory, centri-
fuged immediately at 4°C for 10 minutes at 1500 g, and
stored at -80°C until analysis. All samples were collected
with informed consent process which was cleared by the
Ethical approval from the National Healthcare Group
Domain Specific Review Board (DSRB, Singapore).
Computational selection of candidate TFs markers
We examined a representative set of OEC microarray
expression data [28], which implicates 19 genes that
were at least 5-fold over-expressed. Among these 19
genes, several were encoding for TFs and three genes
were from the keratin group. Since keratins are
involved in the cell integrity, we were interested to
find if the over-expressed TF encoding genes are sub-
jected to the same control mechanism as keratins or if
the corresponding TFs are involved in the control of
keratin genes. This would suggest a possibility that an
over-expressed TF encoding genes may result in over-
production of the corresponding TFs that may leak out
of cell in case of cell damage, making them available in
body fluids, such as blood. Through analysis of promo-
ter content of these 19 genes, we found genes that
share a common promoter model and thus share com-
mon promoter elements (PEs). By a PE we consider a
TF binding site (TFBS) and the DNA strand where
TFBS is found. For example, in our notation “AREB6/-
1” represents a PE that involves AREB6 binding site
found on the reverse complement DNA strand. Tran-
scription start sites (TSSs) of the analyzed promoters
were determined using the same procedure as
described by [29]. The procedure resulted in 10,255
highly accurate human promoters and we considered a
region of [-800, +200] relative to the experimentally
confirmed TSSs. Promoters’ genomic sequences were
extracted from the human genome release hg17 from
http://hgdownload.cse.ucsc.edu/downloads.html#hu-
man. We used all available mammalian matrix models
for TFBSs contained in TRANSFAC Professional data-
base ver. 7.4, and mapped them to the promoter
sequences. The minSUM profiles were used for thresh-
old of the matrix models since these are based on the
optimization that provides the minimum sum of false
positive and false negative predictions of putative
TFBSs. We compared promoter content of 19 overex-
pressed genes against the remaining human promoters,
and calculated the overrepresentation index (ORI)
based on the method introduced by [29,30]. The
method has been successfully applied in several studies
[29,31] and others. All TFBSs mapped to promoters
were ranked according to decreasing ORI values. We
analyzed content of promoters of 19 over-expressed
genes based on mapped TFBSs that had ORI not less
than 1.5. Based on that analysis we found the promoter
model characteristic of the keratin gene group and
respective PEs. The promoter model was characterized
by the presence of AREB6/-1 PE, and one or more of
the following three PEs: GBF/-1, Kr/+1 and XPF-1/-1.
Additional six genes (E2F5, PAX8, ELF3, WFDC2
(HE4), MUC1, LCN2) from the 19 analyzed shared this
promoter model, while the other 10 were void of such
combinations. Thus, three genes encoding for TFs,
E2F5, PAX8 and ELF3 were subjected to the same
putative control model and also were found over-
expressed in OEC. Consequently, we found four candi-
date TFs (AREB6, E2F5, PAX8, ELF3) that have a
potential to play a role in OEC. More details on the
modalities followed for analyzing over expressed genes
in ovarian cancer and potential utility of transcription
factors as therapeutic application is described in Addi-
tional file 1.
Malignancy prediction
We analyzed how well malignant cases can be predicted
using Risk Malignancy Index (RMI), other clinical indi-
cators and E2F5 status. In total, we considered 38
benign cases, and 48 malignant cases (16 early and 32
late). We had 13 features associated with each of the
cases. The thirteen features we used include (1) age (2)
stage of ovarian cancer at the time of detection (3)
serum CA125 levels (4) size(cm) (5) ascites (6) metas-
tases (7) presence of multilocular cyst (8) solid area (9)
bilateral (10) ultrasound score (11) menopause score
(12) RMI and (13) E2F5 status. Due to relatively small
number of cases we first generated a set of 602 artificial
cases based on the set of 86 benign and malignant ones,
using the so-called The Synthetic Minority Oversam-
pling Technique (SMOTE) algorithm [32]. We then
applied the Kstar algorithm [33] to train the machine
learning system to distinguish between malignant and
benign cases using the artificial set of 602 cases. Then
we applied the trained system to the original 86 cases.
We conducted three experiments. In the first one we
used all 13 features. In the second one we excluded
from the original 13 features CA125 information. In the
third one we excluded from the original 13 features the
E2F5 status.
The classification performance was expressed using
the accuracy and F-measure (for other measures of pre-
diction quality see [34]). In what follows tp, tn, fp, fn
stand for true positive, true negative, false positive, and
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false negative predictions, respectively. Accuracy is
defined as:
Accuracy tp tn tp tn fp tn= + + +* / ( ),
while F-measure is defined as
F-measure sensitivity ppv sensitivity ppv= +2* * / (( ),
where sensitivity and ppv (positive predictive value)
are
sensitivity tp tp fn= +/ ( ),
ppv tp tp fp= +/ ( ).
Tissue microarray studies (TMA) studies
A total of 135 formalin-fixed, paraffin-embedded ovarian
tissue samples (111 (43 + 68) benign and malignant
tumors and 24 normal) from the National University Hos-
pital of Singapore were arrayed as previously described
[35]. These cases represented a cross-section of normal/
physiological ovarian tissue-types, benign neoplasms and
ovarian malignancies (see Table 2 for details). Briefly,
hematoxylin and eosin-stained sections were reviewed to
annotate representative tumor and normal areas. These
were sampled with a 1.0-mm diameter tissue cylinder for
normals and benign tumors and a 2.0-mm diameter tissue
cylinder for borderline and malignant tumors and depos-
ited into a “recipient” block using a tissue arraying instru-
ment (ATA100, CHEMICON International Inc,
Temecula, CA). Of the 68 malignant tumours, 7 serous
tumours, 4 endometroid tumours, 2 clear cell tumours, 2
high grade adenocarcinomas not further characterized and
3 mixed epithelial tumours were arrayed in double
punches due to bilateral ovarian involvement and to
account for tumour heterogeneity. After TMA construc-
tion, 4-μm sections were prepared for hematoxylin and
eosin staining verification of the accuracy of the TMA
construction, and for E2F5 antibody analysis. This
approach, in our hands, ensures a reliable representation
of the biology of the tumour, when compared with full
section analysis, and has been tested before in the confir-
mation of other novel biomarkers [36]. Immunohisto-
chemistry was performed using the polyclonal antibody to
the E2F5 transcription factor (ACRIS Antibodies GmbH,
Germany), optimized in our laboratory for immunohisto-
chemistry on full sections and TMA slides of formalin
fixed, paraffin embedded tissues with a protocol that
includes microwaving for heat induced epitope retrieval in
DAKO Target Retrieval Solution at pH9 for 20 minutes.
Our positive control cases used for the optimization of the
antibody, comprising normal epidermis, showed expected
staining for E2F5 in the basal and granular layers [37].
Our negative control was a sample from normal ovary.
Not only was the sample negative throughout, there was
also no background staining. The expression of E2F5 anti-
body was found to be cytoplasmic. While the expression
for the antibody was not very strong, there was indeed a
significant difference from normal and benign ovarian tis-
sue. The results were independently scored by an experi-
enced observer (BP) and confirmed by a second one
(MST). The scoring system suggested a positive result if
Table 2 Summary of Immunohistochemistry results for E2F5 antibody tested on OEC
Type of tissue Number of cases Number positive Percentage positive
Fimbrial/Paratubal/Paraovarian cyst 6 0 0
Surface epithelium/inclusion cysts 14 0 0
Endometriotic cyst 4 0 0
Serous cystadenoma 8 0 0
Mucinous cystadenoma 5 0 0
Benign stromal tumour 4 0 0
Dermoid tumour (mature) 12 0 0
Total 67 0 0
Early and late malignant cases
Serous borderline and malignant E6; L8 24 (4+20) 11(2+9) 45.8
Mucinous borderline and malignant E11; L1 13 (6+7) 4(1+3) 30.77
Endometroid borderline and malignant E7; L5 16 (2+14) 8(1+7) 50
Clear cell carcinoma E2; L1 4 0 0
Adenocarcinoma (not further specified) E2; L2 4 2 50
Mixed adenocarcinoma E3; L1 7 6 85.7
Total 68 31 45.6
Note: Stage I/II (E); Stage III/IV (L) and data not available 5
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there was any detectable cytoplasmic staining in the
lesional cells of interest as can be seen from representative
photomicrographs. The concordance between the two
independent observers was 100%, highlighting the robust-
ness of the analysis.
Measurement of CA-125 level in serum and cyst fluid using
sandwich ELISA method
The CA-125 levels were determined using a CA-125
ELISA kit (Alpha Diagnostic International, San Antonio,
Texas, USA). The samples were diluted ten times using
wash buffer and 25 μl of standards, control, and samples
were pipetted into a 96-well plate in duplicate. Next,
100 μl of biotinylated anti-CA-125 capture antibody was
loaded and the plate was incubated for 2 hours at room
temperature. After washing, 100 μl of HRP conjugated
anti-CA-125 antibody was added and the plate was
incubated for 1 hour at room temperature followed by
addition of substrate and the stop solution. The absor-
bance was read at 450 nm using the ELISA reader
(Tecan, Seestrasse, Männedorf, Switzerland).
Western blotting
Once blood was collected it was allowed to clot. After cen-
trifugation, the supernatant was collected and protein con-
tent was evaluated by the Bradford assay. To perform
Western blot analysis for AREB6, ELF3, PAX8 and E2F5,
20 μg of protein from each sample was separated using
10% sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis. Following electrophoresis proteins bands were
transferred onto nitrocellulose membranes (Hybond-C
Extra) (Amersham Biosciences UK Limited Buckingham-
shire, UK). Filters were blocked in TBST containing 5%
dried skimmed milk and 0.05% Tween-20 for 1 hr at room
temperature. Thereafter, the filters were incubated over
night at 4°C with primary antibodies diluted in TBST con-
taining 5% skimmed milk and 0.05% Tween-20. Primary
antibodies directed against the AREB6 (AVIVA Systems
Biology, San Diego, California, USA), E2F5 (Acris GmbH,
Hiddenhausen, Germany), PAX8 (Abcam Limited, Cam-
bridge, UK), and ELF3 (Orbigen Inc, San Diego, CA) were
chosen as the four TFs suggested by the bioinformatics
analysis. Filters were washed 3 times 10 minutes each with
TBST (0.05% Tween-20). They were subsequently incu-
bated with HRP conjugated secondary antibody diluted
1:5000 in TBST containing 5% dried skimmed milk and
0.05% Tween-20 for 45 minutes at room temperature.
Immunoreactivity was detected using the SuperSignal
West Pico Chemiluminescent Substrate (Pierce biotech-
nology Inc, Rockford, USA) and once blotted the mem-
branes were exposed to Pierce CLXPosure Film (Pierce
biotechnology Inc, Rockford, USA).
Statistical Analysis
The usefulness of E2F5, CA125, and their combinations
as diagnostic markers to differentiate normal cases,
benign, early and late malignant tumors were assessed
using ROC analysis with sensitivity, specificity, positive
& negative predictive values (PPV & NPV) presented.
Analyses were performed using SPSS 15.0 (SPSS Inc.,
Wacker Drive, Chicago, Illinois) with statistical signifi-
cance set at p < 0.05.
Results
Bioinformatics analysis
We identified TF encoding genes that were putatively
controlled by PEs common to the keratin group (KRT8,
KRT13, KRT18) (Figure 1), and are also previously
reported to be at least 5-fold over-expressed in early
and late stage ovarian cancer. Analysis suggests that
these three keratin genes are controlled by AREB6/-1,
and at least one of GBF/-1, Kr/+1, or XPG-11/-1 PEs.
This keratin ‘promoter model’ is also shared with the
three TF encoding genes (E2F5, PAX8, ELF3) and the
other three genes (from the group of 19 analyzed).
These other three genes are MUC1 (GeneID 4582, cell
surface mucin glycoprotein, epithelial membrane anti-
gen) which is elevated in the serum of patients with
breast cancer [38]; WFDC6 (HE4) (GeneID 140870) a
small serine proteinase inhibitor [39] that is part of a
family thought to be a potential OEC marker [40] and
LCN2 (GeneID 3934, lipocalin 2, oncogene 24p3) which
has been shown to be an epithelial inducer in Ras malig-
nancy and a suppressor of metastasis [41]. The outcome
of our analysis suggested four TFs as potential diagnos-
tic markers for OEC: E2F5, PAX8, ELF3 and AREB6.
The logic of selecting these four TFs is as follows. Kera-
tins are proteins involved in cellular integrity. Their
abnormal expression may cause cell brake, thus allowing
cell content to leak out and enter into body fluids
[42-44]. Consequently, over-expressed TF encoding
genes could result in overexpressed TFs that could thus
enter blood and may be detectable there. This suggests
that E2F5, PAX8 and ELF3 are candidates for this type
of test as they are likely to be controlled in a similar
fashion as the three keratin genes we considered and are
also highly co-expressing with them in OEC conditions.
AREB6 is the compulsory component of our putative
‘keratin promoter model’. Although not over-expressed
in OEC it could be the trigger of over-expression of ker-
atins and the implicated three TFs. Thus we included it
in our test list of potential markers.
Tissue array studies
IHC on ovarian TMA constructs of normal ovarian
epithelium, benign ovarian cysts, and early and late
OECs showed that E2F5 expression was completely
absent in all normal and benign samples tested (Figure
2; Table 2). Most of the E2F5 activity was localized in
the cytoplasm with occasional nuclear membrane
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accentuation (See figure 2). In approximately half of all
epithelial ovarian borderline and malignant tumours,
which included serous, mucinous, endometroid and
other subtypes, E2F5 expression was demonstrable by
IHC, compared with none of the normal and benign
cases (z = 6.1; p < 0.001; n = 135) (Table 2). The follow-
ing expression pattern was observed for the different
classes of OEC used for the current study (Table 2); Ser-
ous borderline and malignancy (11/24), Mucinous bor-
derline and malignancy (4/13), Endometroid borderline
and malignancy (8/16), Clear cell carcinoma (0/4); Ade-
nocarcinoma NOS (2/4); and Mixed adenocarcinoma (6/
7). Relatively high expression of E2F5 was found in
endometroid and serous carcinoma than in other types
of OEC. There was no difference in the IHC expression
pattern observed between the right and left ovaries
where tumour was bilateral.
Detection of candidate proteins in serum using
western blot
Potential markers identified though bioinformatic
approach were validated using western blotting approach.
Transcription factors AREB6, PAX8, and ELF3 (Figure
3A) showed inconsistent patterns of expression when the
study was carried on a limited number of samples. For
TF AREB6, expression was found only in one malignant
sample, while for PAX8 and ELF3 the expression pattern
was present in normal and cancer samples. E2F5 expres-
sion was found to be prominent in cancer samples (early
and late malignant cases) and not in normal serum sam-
ples. Hence, we carried out a comprehensive testing for
E2F5 expression pattern on a total of 144 samples com-
prising of 56 normal; 40 benign, 16 early, and 32 late
cases (Figure 3B). E2F5 expression (Table 3) was found
in 23.21% (13 out of 56) healthy volunteers, but was pre-
sent in 81.25% (39 out of 48: 16 early and 32 late cases; n
= 48) of OEC patient serum. There was only 42.5% (17/
40) expression of E2F5 in benign cases. Our data suggest
that E2F5 could prove a highly discriminatory marker for
detection of OEC, and in particular early OEC. Among
the different subtypes of OEC, different expression pat-
tern was observed between early and late types. In the
early stage carcinoma, stage I/II endometroid (5/6); ser-
ous carcinoma (1/2); mucinous carcinoma (4/4); clear
Figure 1 Genes putatively controlled by tentative promoter model of keratin group. Summary of the main finding in analysis of 19 genes
over-expressed in ovarian cancer.
Kothandaraman et al. BMC Cancer 2010, 10:64
http://www.biomedcentral.com/1471-2407/10/64
Page 6 of 13
Figure 2 Differential expression pattern of E2F5 in ovarian tumour specimens examined by immunohistochemistry. A, benign serous
cystadenoma, B, epithelial inclusion cyst, C, cystic serous carcinoma, and D, endometrioid adenocarcinoma samples. The low power
photomicrograph in each section shows the full tissue microarray “punch” (x100), while the high power photomicrograph shows detail of the
antibody expression (x600). There is no E2F5 expression in normal and benign tissue (A, B), but significant expression in ovarian epithelial cancer
(C, D).
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cell carcinoma (3/3) and others (1/1). In the stage III/IV
cases of OEC cases the endometroid (8/9); serous carci-
noma (15/19); mucinous carcinoma (1/1); clear cell carci-
noma (1/3). Similar to tissue array results endometroid
and serous carcinoma showed increased over expression
of E2F5 compared to other types of OEC (cc = 0.47).
CA125 assays
Only 75% of early cancer cases showed higher levels of
CA125 compared to 87.5% for E2F5 expression in early
OEC cases (Table 3). However, for late and benign cases




Figure 3 Validation of potential target (AREB6, PAX8, ELF3) using western blots (A) and expression of E2F5 in serum from normal,
benign and, malignant patient samples (B). (A) Target validation using western blots of AREB6, PAX8, ELF3, in serum of healthy volunteers (N)
(n = 2), patients with benign ovarian cysts (B1, B2) (n = 2), and patients with late- (L1, L2) (n = 2) and early-stage (E1-E3) (n = 3) serous
adenocarcinoma. AREB6 was overexpressed in late stage disease, but was not discriminatory for early cancer. PAX8 and ELF3 were equally
expressed in all serum samples. (B) Expression of E2F5 in serum from normal (n = 56), benign (n = 40) and, malignant (n = 48) serum obtained
from patients with cancer of the ovary.
Table 3 Details of E2F5/CA125 expression pattern on




Yes No Yes No Yes No
Serous neoplasms 3/3 2/3 1/1 1/1 15/18 4/1
Mucinous neoplasms 4/1 7/10 4/3 0/1 1/1 0/0
Endometroid neoplasms 6/9 8/5 5/5 1/1 8/8 1/1
Clear cell neoplasms 0/0 0/0 3/2 0/1 1/1 2/2
Others 4/5 6/4 1/1 0/0 0/0 0/0
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showed no correlation between CA125 and E2F5
expression pattern (between different subtypes and
between early and late in E2F5 and CA125).
Statistical inference on CA125 and E2F5 expression in
normal and malignant cases
Using data from 144 samples we checked the expres-
sion for both E2F5 and CA125 on serum from normal
condition, benign cyst, malignant cyst (early and late
conditions). We evaluated E2F5 either alone or in
combination with CA125 for their efficacy in monitor-
ing the malignancy status for OEC. We looked at the
following conditions for their efficacy in diagnosing
OEC and for accessing the sensitivity as well as specifi-
city in diagnosing the malignancy associated with ovar-
ian cancer: (1) CA125 used alone; (2) E2F5 used alone;
(3) both E2F5 and CA125 negative; (4) at least one
positive for either CA125 or E2F5; (5) at least one
negative for either CA125 or E2F5; and (6) both posi-
tive for CA125 and E2F5,. A unique trend in the pat-
tern of expression was observed for E2F5 along with
CA125. Presence of CA125 or E2F5 in sera resulted in
the increase in sensitivity, while a test positive for both
CA125 and E2F5 led to a major increase in the specifi-
city, PPV and NPV. This demonstrates that E2F5 is
characteristic for a different subclass of individuals
compared to CA125 which justifies utilization of E2F5
jointly with CA125.
From a clinical stand point, the key issue is to know
the malignancy status of a cyst following a positive
ultrasound scan for a cyst. To answer the question, after
identification of a cyst using ultrasound, we used a com-
bination of CA125 and E2F5. If both were absent, it
could be considered as non-cancer case with 93.75%
NPV, while the presence of either CA125 or E2F5 is
capable of detecting OEC in 97.92% of the actual cancer
cases (sensitivity). The presence of both CA125 and
E2F5 makes the specificity as high as 72.50% as com-
pared to CA125 alone (55%), E2F5 alone (55%) or
“CA125 or E2F5” (37.5%). However, more samples have
to be tested to assess real clinical utility of E2F5 as a
biomarker for OEC.
The mixture of samples obtained from different ethnic
populations prompted us to look into the association of
race with the incidence of disease. The study showed
that race did not have a role in the incidence of disease
while considering expression pattern of both E2F5 and
CA125. Similarly, while taking into account the age >40,
as well as factors such as ethnicity and age >40, was
also found to have no correlation with the occurrence of
the disease. Our retrospective analysis therefore provides
evidence that E2F5 could also be a useful independent
prognostic indicator in patients with OEC as it targets
different phenotypes compared to CA125. Moreover, the
combined use of E2F5 and CA125 increases accuracy of
OEC diagnosis significantly. Overall, our data suggest
that presence of E2F5 in preoperative sera is associated
with better survival outcome. More studies are, however,
warranted to confirm these findings.
Malignancy prediction
Using 38 benign and 48 malignant cases, we generated
an additional artificial set of 602 cases using SMOTE
algorithm. We trained the Kstar classification model on
this artificial data set of 602 cases and then applied so
trained model to the original 86 cases (48 malignant
and 38 benign). The goal is to identify malignant cases.
Our method was able to predict 47 out of 48 malignant
cases as malignant, and had one benign case predicted
wrongly as being malignant. This produced sensitivity of
97.92% (47/48), ppv of 97.92%, and specificity of 97.37%
(37/38) (Table 4). At the same time, RMI > 200 criter-
ion produces sensitivity of 77.08% (37/48) and specificity
of 92.11% (35/38) (Table 5). Consequently, the F-
measure and accuracy of the new method for assessing
malignancy is increased from 84.08% and 83.72% based
on RMI > 200 criterion up to 97.92% and 97.67%,
respectively. Moreover, there is an increase of 20.84% of
absolute scale in sensitivity with the new method, while
simultaneously it increased specificity by 5.56% of abso-
lute scale. Overall, this is a significant increase in accu-
racy. We evaluated the contribution of both CA125
biomarker and E2F5 status to the accuracy of separation
of malignant from benign cases (Table 5). For that, we
first excluded information about CA125 from the set of
13 features we considered. The sensitivity remained the
same as with the all 13 features, but specificity was
reduced to 94.74%. In another experiment we excluded
from the original 13 features the E2F5 status. The sensi-
tivity remained the same as when the original 13 feature
are used, but specificity reduced to 92.11%. Thus, the
addition of E2F5 to the set of features that we used
reduces the false positive cases 3-fold (from 7.89% to
2.63%). These results demonstrated that only by the use
of both CA125 and E2F5 information in combination
with the other clinical features, one achieves the best
classification performance. Thus the information about
E2F5 status has proved to be beneficial for predicting
malignancy.
Table 4 Malignancy prediction using Kstar classification





Sensitivity 97.92% (47/48) 77.08%(37/48)
Specificity 97.37% (37/38) 92.11%(35/38)
PPV 97.92% 92.5%
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Discussion
There is increasing evidence on the role of TFs as mar-
kers for cancer [24-26], as potential prognostic markers
[45], and as targets for drug therapy [46]. Our assump-
tion was that regulatory genes that are differentially
over-expressed during the development and progression
of OEC are likely to alter simultaneously the expression
of many genes in the considered disease state, and that
upregulation of gene clusters and an abnormal elevated
expression of several unrelated genes could be explained
if they shared similar promoter model, thus being
potentially subjected to the similar regulatory mechan-
ism. If the identified TFs are to have any utility as clini-
cal markers, the ability to differentiate healthy controls
and patients with benign conditions from patients with
early-stage disease (as opposed to advanced-stage dis-
ease) is essential.
Regarding E2F5 we have unambiguously shown that it
is characteristic for a group of patients different from
those that have elevated CA125. This means that cases
that will slip through CA125 test could be captured by
E2F5 status. Second, we did show that E2F5 status has
been remarkably specific and indicative on the tissue
array tests. Thirdly, using E2F5 status in addition of
other clinical indicators, enabled us to obtain extremely
high accuracy in separation of malignant from benign
cases that was not possible without E2F5.
Given the higher E2F5 levels in malignant tissues,
approximately half of all malignant tissues showed
expression for E2F5 while none of the normal and
benign samples showed expression for E2F5. E2F5
belongs to the family of E2F TFs which are both prolif-
eration promoting and proliferation inhibiting TFs, and
E2F5 falls in the later category [47]. It is likely that ele-
vated E2F5 levels might be attributed to its increased
production during cancer as a means by the body to
arrest the proliferation of tumour cells during the early
stage of the disease. Our study on E2F5 in tissues and
serum establishes the importance of E2F5 (a prolifera-
tion inhibiting gene), [48] as a potential marker for early
OEC. Other studies also showed similar observations for
this protein. E2F5 was found to be upregulated (5 fold)
in early and late stage ovarian tumours [28]. Also, stu-
dies conducted using custom made microarray specific
for OEC (Ovachip) showed upregulation of E2F5 in
OEC [49], and it is found to play a key role in the neo-
plastic transformation of various cancer tissues as
identified using microarray analysis [19]. Similar obser-
vations were recently highlighted by microarray experi-
ments conducted on sporadic colorectal carcinoma
tissues showed upregulation of E2F5 genes during
malignancy [50,51]. The oncogenic property of E2F5
was discovered by the amplified E2F5 expression in pri-
mary rodent cells as well as in breast cancer tumours
[52]. While in other cancers, a high molecular weight
E2F complex is detected within human colon carcinoma
cells when the cell-cycle is disrupted [53]. It was found
that interferon-gamma treatment for ovarian cancer
caused a reduction of the proliferation-promoting TFs
E2F1 and E2F2, at the same time it also increased the
inhibiting TFs E2F4 and E2F5[54]. This observation
highlights the significance of E2F cross-talk in the anti-
proliferative function of interferon-gamma [54].
E2F class of cell-cycle genes happen to be the key
transcription factors involved in the transition from G
to G1 phase have been recently the focus of attention
for gynecological cancers [55]. E2F genes are a family of
genes comprising 8 different genes identified till to-date
[48]. G1-S-phase transition in normal cells requires
phosphorylation of the retinoblastoma protein pRb and
the related proteins pRb2/p130 and p107 by CDKs. This
process results in the release of E2F transcription factors
controlling various genes required for DNA synthesis
and cell-cycle control. Role of cell-cycle genes [22] and
imbalance in the regulation of genes promoting and
inhibiting cellular proliferation and apoptosis has been
implicated in the oncogenesis of OEC [56]. Alteration in
genetic control in cancers is usually attributed to base
pair mutations, but may also occur due to TF deregula-
tion [55]. Deregulation of both proliferation-promoting
and proliferation-inhibiting E2F TFs and their cross-talk
were reported to influence the clinical outcome [55].
DNA amplifications for E2F5 (8p22-q21.3) has been
observed during sporadic colorectal cancers [51]. The
above evidence suggests that E2F5 is similar to MYC-
type cooperating oncogene and persistent unregulated
expression of E2F5 can assist other oncogenes to pro-
mote cell transformation. Along with chromosomal
amplifications and overexpression of the E2F5 gene as
detected in breast tumors suggests that E2F5 deregula-
tion may have a role in human tumor development [52].
TFs have been described as markers for cancer as well
as markers for prognostication [26,45,46]. TF Ets-1 has
been found to have significant prognostic value for
Table 5 Diagnostic accuracy developed for ovarian cancer detection with 13 features using Kstar classification based
on SMOTE algorithms.
With 13 features CA125 excluded from 13 features E2F5 excluded from 13 features RMI > 200
Sensitivity 97.92% 97.92% 97.92% 77.08%
Specificity 97.67% 94.74% 92.11% 92.11%
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relapse-free survival as an independent predictor of poor
prognosis in breast cancer. This observation correlates
to its role in transcriptional regulation of factors
involved in angiogenesis such as VEGF and extracellular
matrix remodeling (PAI-1) [57]. Another TF, thyroid
transcription factor 1 (TTF-1) has been found as a good
prognostic factor for survival in non-small-cell lung can-
cer (NSCLC). Its effect appears also significant when the
analysis is restricted to patients with adenocarcinoma
[45]. Similarly microphthalmia TF has been reported as
a marker for circulating tumor cell detection in blood of
melanoma patients [26].
One can raise a question why it should be possible to
look for TF in sera as biomarkers of ovarian cancer.
Our methodology has been to look for those TFs that
potentially affect genes producing proteins that influence
extracellular matrix, or to those TFs that are both co-
regulated and co-expressed with such genes. In our case
we focused on keratins. We hypothesize that interplay
of extracellular matrix and cancerous cells makes them
more prone to braking so that cancer cell content leaks
out and enters lymph and blood systems[42]. For this
reason we expect to be able to find E2F5 in serum of
patients with early and late stage OEC and our experi-
mental results suggest that this may be the case.
Finally, one may argue that it was not necessary to do
any bioinformatic analysis of gene expression data and
directly test all over-expressed TFs. It is true that it was
possible to make such tests directly, but our analysis
enabled us focus on specific TFs, and also has provided a
potential explanation for the co-expression of E2F5 and
keratin genes in OEC based on the putative co-regulation
mechanism suggested by our derived promoter model.
Conclusion
Our findings provide additional support for the involve-
ment of the E2F5 gene which belongs to the E2F family
of genes in human OEC development and progression.
While additional larger prospective studies are essential
to validate our findings, we have demonstrated that the
application of microarray analysis can facilitate the iden-
tification of genes, genetic pathways, and proteins that
are not only involved in the pathogenesis of OEC but
also may represent potential serum markers.
Additional file 1: Details of the modalities followed for analyzing
over expressed genes in ovarian cancer. (1) the details of the
modalities performed for analyzing overexpressed genes in ovarian
cancer (2) information on transcription factors AREB6 and PAX8 (3) a
description on the potential utility of transcription factors in therapeutic
applications and (4) relevant references for this section.




CA125: Cancer antigen 125; OEC: Ovarian Epithelial Cancer; FIGO;
International Federation of Gynecology and Obstetrics; ORI: Over
Representation Index; PE: Promoter Element; PPV: Positive Predictive Value;
NPV: Negative Predictive Value; SMOTE: Synthetic Minority Oversampling
Technique; TMA: Tissue Microarray; IHC: Immunohistochemistry; TF:
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